CARDIFF ONCOLOGY, INC. Lessor, Operating Lease, Payment to be Received, Year Five
CARDIFF ONCOLOGY, INC. (CRDF) had Lessor, Operating Lease, Payment to be Received, Year Five of $0 as of 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Notes › Leases › Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity
us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears · last filed 2019-11-07
- 2019-09-30: Lessor, Operating Lease, Payment to be Received, Year Five $0.00.
- 2019-06-30: Lessor, Operating Lease, Payment to be Received, Year Five $0.00.
- 2019-03-31: Lessor, Operating Lease, Payment to be Received, Year Five $0.00.
| Period end | Lessor, Operating Lease, Payment to be Received, Year Five |
|---|---|
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |